Source: EURLEX
Language: en
Format: md

201806290581986302018/C 249/318032016TC24920180716EN01ENINFO\_JUDICIAL20180606252622

Case T-803/16: Judgment of the General Court of 6 June 2018 — Glaxo Group v EUIPO — Celon Pharma (SALMEX) (EU trade mark — Invalidity proceedings — EU figurative mark SALMEX — Earlier three-dimensional national mark — Competence of the Board of Appeal to examine of its own motion whether the earlier mark had been put to genuine use — Article 64(1) and Article 76(1) of Regulation (EC) No 207/2009 (now Article 71(1) and Article 95(1) of Regulation (EU) 2017/1001))

[Top](#document1)

C2492018EN2520120180606EN0031252262

Judgment of the General Court of 6 June 2018 — Glaxo Group v EUIPO — Celon Pharma (SALMEX)

(Case T-803/16) (
[1](#t-C_2018249EN.01002502-E0001)
)

‛(EU trade mark — Invalidity proceedings — EU figurative mark SALMEX — Earlier three-dimensional national mark — Competence of the Board of Appeal to examine of its own motion whether the earlier mark had been put to genuine use — Article 64(1) and Article 76(1) of Regulation (EC) No 207/2009 (now Article 71(1) and Article 95(1) of Regulation (EU) 2017/1001))’

2018/C 249/31Language of the case: English

Parties

Applicant: Glaxo Group Ltd (Brentford, United Kingdom) (represented by: S. Baran, T. St Quintin, S. Wickenden, Barristers, E. Morris and R. Jacob, Solicitors)

Defendant: European Union Intellectual Property Office (represented by: D. Hanf, acting as Agent)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Celon Pharma S.A. (Łomianki, Poland) (represented by: M. Krasiński, lawyer)

Re:

Action brought against the decision of the Fourth Board of Appeal of EUIPO of 31 August 2016 (Case R 2108/2015-4) relating to invalidity proceedings between Glaxo Group Ltd and Celon Pharma.

Operative part of the judgment

The Court:

| 1. | Annuls the decision of the Fourth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 31 August 2016 (Case R 2108/2015-4); |

| 2. | Orders EUIPO to bear its own costs and those incurred by Glaxo Group Ltd during the proceedings before the General Court; |

| 3. | Orders Celon Pharma S.A. to bear its own costs relating to the proceedings before the General Court. |

---

(
[1](#c-C_2018249EN.01002502-E0001)
) [OJ C 22, 23.1.2017](./../../../legal-content/EN/AUTO/?uri=OJ:C:2017:022:TOC).

[Top](#document2)